Ana A. Lopez-Martin

Salamanca, CL, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Fecal calprotectin as a biomarker for the diagnosis of gastrointestinal graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Fecal calprotectin as a biomarker for the diagnosis of gastrointestinal graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Journal: Bone marrow transplantation
Published: January 12, 2026

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

Journal: HemaSphere
Published: December 28, 2025

EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study.

EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study.

Journal: Transplantation and cellular therapy
Published: August 07, 2025

Impact of the kinetics of circulating anti-BCMA CAR-T cells and normal lymphocytes on the outcome of MM patients.

Impact of the kinetics of circulating anti-BCMA CAR-T cells and normal lymphocytes on the outcome of MM patients.

Journal: HemaSphere
Published: April 10, 2025

Nabiximols oromucosal spray in patients with chronic graft-versus-host disease: effects on sclerodermatous features and refractory muscle cramps.

Nabiximols oromucosal spray in patients with chronic graft-versus-host disease: effects on sclerodermatous features and refractory muscle cramps.

Journal: Bone marrow transplantation
Published: January 30, 2025

Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy.

Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy.

Journal: Leukemia
Published: January 11, 2025

GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation.

GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation.

Journal: Bone marrow transplantation
Published: October 21, 2024

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment.

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment.

Journal: Journal of hematology & oncology
Published: July 22, 2024

Quantifying HLA Mismatches at Epitope Level in Haplo-HSCT: Impact in the Outcome in Strategies Using PTCy.

Quantifying HLA Mismatches at Epitope Level in Haplo-HSCT: Impact in the Outcome in Strategies Using PTCy.

Journal: HLA
Published: April 16, 2024

Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells.

Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells.

Journal: HemaSphere
Published: February 05, 2024

A research center's experience of T-cell-redirecting therapies in triple-class refractory multiple myeloma.

A research center's experience of T-cell-redirecting therapies in triple-class refractory multiple myeloma.

Journal: Blood advances
Published: January 26, 2024

Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.

Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.

Journal: HemaSphere
Published: October 29, 2023
Showing 1-12 of 14

Last Updated: 09/26/2026